Sibutramine : review of its cardiovascular risk-benefit profile

The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients

Moderate weight loss improves metabolic and cardiovascular risk factors and prevents the progression to Type 2 diabetes. Furthermore, a healthy lifestyle is associated with lower cardiovascular mortality, whereas sustained weight loss and increased fitness are both associated with reduced cardiovascular mortality. Currently available antiobesity drugs have been shown to deliver moderate weight ...

The use of sibutramine in the management of obesity and related disorders: An update

AIMS To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. METHODS AND RESULTS The most important articles on sibutramine up to January 2009 were located by a PubMed and Medline search. Sibutramine reduces food intake and body weight more than placebo and has positive effects on th...

VHRM-4027-The use of sibutramine in the management of obesity

Correspondence: Themistoklis Tzotzas Al. Svolou 27, 54622, Thessaloniki, Greece Tel +30 23 1028 7490 Fax +30 23 1028 4827 email [email protected] Aims: To review the major trials that evaluated the efficacy and safety of the use of sibutramine for weight loss and the impact of this agent on obesity-related disorders. Methods and results: The most important articles on sibutramine up to January ...

Author's response to reviews Title: The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period Authors:

Sibutramine on Cardiovascular Outcome

S ibutramine, a combined norepinephrine and serotonin reuptake inhibitor, is effective in the management of obese patients requiring pharmacotherapy as part of a multimodal approach to weight loss. It improves insulin resistance markers, glucose metabolism, and atherogenic dyslipidemia in both diabetic and nondiabetic patients, most of these effects resulting fromweight loss. However, sibutrami...